Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada

BACKGROUND: Heart failure (HF) with reduced ejection fraction represents approximately 50% of the 600,000 Canadians currently living with HF and over 90,000 new cases diagnosed each year. The angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, demonstrated superior efficacy in reducing...

Descripción completa

Detalles Bibliográficos
Autores principales: Huitema, Ashlay A., Daoust, Alexia, Anderson, Kim, Poon, Stephanie, Virani, Sean, White, Michel, Rojas-Fernandez, Carlos, Zieroth, Shelley, McKelvie, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499363/
https://www.ncbi.nlm.nih.gov/pubmed/32995716
http://dx.doi.org/10.1016/j.cjco.2020.03.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499363/
https://www.ncbi.nlm.nih.gov/pubmed/32995716
http://dx.doi.org/10.1016/j.cjco.2020.03.015

Ejemplares similares